Nam Myeong-Ok, Hahn Soojung, Jee Joo Hyun, Hwang Tae-Sun, Yoon Ho, Lee Dong Hyeon, Kwon Min-Soo, Yoo Jongman
Department of Microbiology and School of Medicine, CHA University, Seongnam-si, Gyeonggi-do 13488, South Korea.
Institute of Basic Medical Sciences, School of Medicine, CHA University, Seongnam-si, Gyeonggi-do 13488, South Korea.
Oncotarget. 2017 Dec 26;9(5):6356-6368. doi: 10.18632/oncotarget.23721. eCollection 2018 Jan 19.
Organoids, a multi-cellular and organ-like structure cultured , can be used in a variety of fields such as disease modeling, drug discovery, or cell therapy development. When organoids derived from Lgr5 stem cells are cultured , recombinant R-spondin-1 protein should be added at a high concentration for the initiation and maintenance of the organoids. Because the addition of large amounts of R-spondin-1 greatly increases the cost of organoids, the organoids grown with R-spondin-1 are not practical for large-scale drug screening and for the development of therapeutic agents. In this study, we tried to find a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein; thus, using organoid media that each included one compound from among an 8,364 compound library instead of R-spondin-1, we observed whether organoids were established from the crypts of the small intestine. As a result, we found one compound that could promote the initial formation and growth of enteroids in the medium without R-spondin-1 and named it RS-246204. The enteroids grown with RS-246204 had a similar differentiation capacity as well as self-renewal capacity as the enteroids grown with R-spondin-1. Furthermore, the RS-246204-derived enteroids could successfully produce the forskolin induced swelling and the organoid based epithelial to mesenchymal transition model. This compound could be used for developing a cost-efficient culturing method for intestinal organoids as well as for exploring Lgr5 signaling, intestinal stem cell physiology and therapeutics for GI tract diseases.
类器官是一种培养的多细胞且类似器官的结构,可用于多种领域,如疾病建模、药物发现或细胞治疗开发。当培养源自Lgr5干细胞的类器官时,应添加高浓度的重组R-spondin-1蛋白以启动和维持类器官的生长。由于添加大量的R-spondin-1会大大增加类器官的成本,因此用R-spondin-1培养的类器官对于大规模药物筛选和治疗剂开发并不实用。在本研究中,我们试图找到一种能够在不使用R-spondin-1蛋白的情况下启动小肠类器官生长的R-spondin-1替代化合物;因此,我们使用含有8364种化合物库中的一种化合物而非R-spondin-1的类器官培养基,观察是否能从小肠隐窝建立类器官。结果,我们发现了一种化合物,它可以在不含R-spondin-1的培养基中促进肠类器官的初始形成和生长,并将其命名为RS-246204。用RS-246204培养的肠类器官与用R-spondin-1培养的肠类器官具有相似的分化能力和自我更新能力。此外,源自RS-246204的肠类器官能够成功产生福斯可林诱导的肿胀以及基于类器官的上皮-间质转化模型。这种化合物可用于开发一种经济高效的肠类器官培养方法,以及探索Lgr5信号通路、肠道干细胞生理学和胃肠道疾病的治疗方法。